Company: SCLXW
Filing Date: 2025-01-17
Form Type: 10-Q
Source: 0000950170-25-006755
Chunk: 21

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 10-Q
Item: Item 2
Chunk 21
---
 September 30, 2024 and 2023 was $41.7 million and $33.3 million, respectively. The increase of $8.4 million was driven by the increase in gross product sales of ZTlido and ELYXYB by approximately 12% and 110%, respectively, driven by the increase in the sales volume and a standard industry annual price increase, and sales of GLOPERBA commencing in June 2024, partially offset by an increase in rebates.

Cost of Revenue

 49

Cost of revenue for the nine months ended September 30, 2024 and 2023 was $12.0 million and $11.2 million, respectively. The increase of $0.8 million was primarily due to an increase in gross revenue of approximately 16%, partially offset by a decrease in logistics costs due to no air shipments used during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023.

Research and Development Expenses

The following table summarizes research and development expenses by project for the nine months ended September 30, 2024 and 2023 (in thousands):

    Nine Months Ended September 30,

    2024

    2023

    Increase (Decrease)

    SP-102

    Contracted R&D
     
    $
    1,032

    $
    1,230

    $
    (198
    )

    Personnel

    410

    212

    198

    Other

    43

    48

    (5
    )

    Total SP-102

    1,485

    1,490

    (5
    )

    SP-103

    Contracted R&D

    1,829

    3,681

    (1,852
    )

    Personnel

    933

    883

    50

    Other

    139

    330

    (191
    )

    Total SP-103

    2,901

    4,894

    (1,993
    )

    SP-104

    Contracted R&D

    25

    583

    (558
    )

    Personnel

    217

    444

    (227
    )

    Other

    (4
    )

    109

    (113
    )

    Total SP